Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Reaches Nine Milestones in Schering Target Validation Deal

NEW YORK, May 9 (GenomeWeb News) - Atugen said today that it reached nine milestones under its target validation research deal with German drug maker Schering and its US subsidiary, Berlex Biosciences.

 

According to Atugen, it received milestone payments on nine of Scheing's cancer drug targets that were validated by Atugen using its proprietary gene-silencing technologies since the companies began working together in 2002.

 

Financial terms of the arrangement, which an Atugen spokeswoman said has now been completed, are undisclosed.

 

 

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.